Search

everythinglearnresearchcommunity

for

Search:↓

PP405 is a promising new treatment for hair loss. It performs three actions in one, potentially offering a cure.

The post and conversation are about a user's 6-month hair loss progress using 0.5 mg dutasteride daily and 2.5 mg oral minoxidil daily. Users congratulate the progress and discuss the effectiveness of the treatment.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

The user reported significant hair regrowth using a topical treatment of 0.3% finasteride and 6% minoxidil, with noticeable progress in five months. The treatment is applied once daily, and the user experienced some initial shedding but no side effects.

A user's two-year progress using 1mg of oral finasteride daily and twice daily application of 5% minoxidil solution for hair loss. The user experienced temporary side effects but is pleased with the results, and another user warns about the importance of consistent use for maintaining results.

The user switched from finasteride to dutasteride while continuing minoxidil and microneedling, seeing gradual hair regrowth. They are considering adding oral minoxidil and possibly a LLLT helmet for further improvement.

A user's progress with treating hair loss using 1mg finasteride per day, with reports of no noticeable side effects and positive results. Other users have shared their experiences with different treatments, such as Dutasteride and Minoxidil.

The conversation humorously discusses a visit to the Everychem laboratory, with a focus on hair loss treatments like Minoxidil, finasteride, and RU58841. The tone is satirical.

ET-02 is seen as promising for addressing hair loss and graying, but PP405 is more advanced in development and has better publicity. Some users plan to use both treatments alongside minoxidil and dutasteride.

The conversation is about the anticipation and uncertainty regarding the release of GT20029 Phase 2 results for hair loss treatment. Users express hope for its effectiveness and minimal side effects compared to other treatments like Pyri and HMI115.

The user has been using topical minoxidil for 1.5 years and dutasteride for 6 months. Opinions on progress vary, with some seeing stabilization and thickening, while others see no significant change.

Topical sodium valproate may promote hair growth by inhibiting GSK3β, allowing beta-catenin to proliferate, but it has potential side effects and requires more research. The conversation also mentions skepticism about a product called Vdphlo1, which includes sodium valproate and other ingredients.

Creatine use with finasteride increased DHT levels, possibly affecting hair loss. The user plans to reduce creatine to stabilize DHT and hair shedding.

User experienced good results with topical finasteride, noting reduced DHT and increased testosterone. They plan to revert to a lower dosage after observing slight libido reduction.

User started using Pantostin Alfatradiol after watching haircafe on YouTube and noticed thicker hair. They wonder why it's not more popular, as it's a 5α-reductase inhibitor with a different mechanism than minoxidil.

The conversation is about treatments for androgenetic alopecia, focusing on hyperresponders. Treatments include Minoxidil, finasteride, RU58841, leg training, and cold therapy.

The conversation discusses a hair loss prevention regimen using a custom topical treatment with Dutasteride, Minoxidil, Latanoprost, Cetirizine, Tretinoin, Vitamin D3, and caffeine, along with supplements like iron, selenium, vitamin D, and vitamin B. The user advises against expensive treatments like LLLT caps and unnecessary natural supplements.

The launch of Pyrilutamide as a potential hair loss treatment, with people discussing whether it is better than treatments like finasteride and minoxidil. Some participants have also discussed the risks associated with importing drugs from China.

The user has been using a treatment of Finasteride 0.3% and Minoxidil 6% since March 3rd, along with microneedling once a week and a DHT blocker. They report good progress in hair growth over two months.

User seeks availability of Breezula and its delayed trials. Asks for success with similar topical antiandrogens like fluridil.

The conversation is about managing allopregnanolone deficiency caused by 5-alpha-reductase inhibitors like finasteride or dutasteride. Specific treatments discussed for hair loss include Minoxidil, finasteride, and RU58841.

The conversation discusses why CB-03-01, a potential hair loss treatment, isn't widely discussed despite evidence of its effectiveness and safety. Some users mention other treatments like melatonin, procianidin b2, and RU58841, debating their effectiveness and safety.

PP405 may revive dormant hair follicles, and DHT blockers like finasteride or dutasteride could maintain new hair. Combining PP405 with minoxidil might be optimal, but long-term effects and continuous use are uncertain.

The acne medication Winlevi, which contains Clascoterone, is available in the U.S. and may slow down hair loss until a higher concentration treatment, Breezula, is released.

Clascoterone 5% solution showed a 539% improvement in hair count compared to placebo, but the actual increase in hair growth is minimal. Users express skepticism about the effectiveness of hair loss treatments.

Chinese company gets green light for Pyrilutamide Phase II trial for androgenetic alopecia. Androgen receptors downregulate in androgen deficient environments.

The user is frustrated with minimal hair regrowth after using dutasteride, oral minoxidil, and previously finasteride and topical minoxidil. Despite feeling discouraged, others suggest continuing treatment as progress can be slow and subtle, with some users noting visible improvement.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

The conversation discusses interest in peptides for hair loss, specifically mentioning ahkCU and ghkCU. A user is considering adding ghkCU to their treatment regimen.

Pyrilutimide, a treatment for hair loss; it's effectiveness compared to other treatments such as Finasteride and RU58841; and some users’ experiences with the treatment.